Athira Pharma
Athira Pharma (operating as LeonaBio) is a clinical-stage biopharmaceutical company developing novel small molecule therapies, with a Phase 3 SERM (lasofoxifene) for metastatic breast cancer and a Phase 1 ALS candidate (ATH-1105), serving patients with high-unmet-need oncology and neurodegenerative diseases.
- Company typePublic
- Founded2011
- HeadquartersSeattle, United States
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What Athira Pharma does
Athira Pharma, Inc., now operating as LeonaBio, is a clinical-stage biopharmaceutical company headquartered in Bothell, Washington, listed on NASDAQ under ticker ATHA. The company develops novel small molecule drug candidates targeting devastating diseases with limited treatment options, with two lead programs: lasofoxifene, a selective estrogen receptor modulator (SERM) currently in Phase 3 development (ELAINE-3) for metastatic breast cancer, and ATH-1105, a small molecule candidate for amyotrophic lateral sclerosis (ALS) that has completed Phase 1 trials in healthy volunteers.
Athira's commercial model is preclinical-stage clinical biopharma: it does not yet generate revenue from product sales and instead finances operations through equity capital, with the most recent transaction being a December 2025 private placement of $90 million (up to $236 million contingent on a regulatory milestone) co-led by Perceptive Advisors, extending cash runway into 2028. The strategic license-in of lasofoxifene from Sermonix Pharmaceuticals in December 2025 repositioned the company from a neurodegenerative-disease-focused pipeline (Alzheimer's/ALS) toward oncology, with lasofoxifene representing the primary value driver and projected by management to achieve peak annual U.S. sales of approximately $1 billion if approved. Topline Phase 3 data for ELAINE-3 is expected in mid-2027.
Upon regulatory approval, Athira/LeonaBio intends to commercialize lasofoxifene through specialty pharmaceutical distribution channels (specialty pharmacies and oncology-focused institutions) across global markets excluding Asia and certain Middle Eastern countries. The company has not yet established commercial infrastructure for direct product sales and currently markets to investors and medical/scientific audiences through investor relations communications, conference presentations (e.g., 5th Annual ALS Drug Development Summit), and medical affairs activities.
Athira Pharma firmographics
Firmographics- Name
- Athira Pharma
- Legal name
- Athira Pharma, Inc.
- Website
- https://athira.com
- Company type
- Public
- Founded year
- 2011
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Athira Pharma (operating as LeonaBio) is a clinical-stage biopharmaceutical company developing novel small molecule therapies, with a Phase 3 SERM (lasofoxifene) for metastatic breast cancer and a Phase 1 ALS candidate (ATH-1105), serving patients with high-unmet-need oncology and neurodegenerative diseases.
- Ownership category
- akta.pro rank
Athira Pharma industry classification
Industry- Product category
- Clinical-Stage Biopharmaceutical Drugs
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)
- akta.pro primary industry
- Oncology Specialty Pharmaceuticals (HLAIACAA)
- akta.pro secondary industries
- Specialty Care Pharmaceuticals (HLAIAAAB), Rare Oncology & Hematologic Malignancy Therapies (HLAIAIAC)
Keywords
Where Athira Pharma is headquartered
LocationHeadquarters
- HQ city
- Seattle
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Athira Pharma business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Revenue model
- Drug commercialization: Pre-revenue clinical-stage biopharmaceutical company. Future revenue will be generated through commercialization of approved drug candidates, including lasofoxifene for metastatic breast cancer and ATH-1105 for ALS, if regulatory approvals are obtained.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels2 records
Athira Pharma product offering
Product offeringCore offering
Athira Pharma (operating as LeonaBio) is a clinical-stage biopharmaceutical company developing novel small molecule drug candidates for devastating diseases with limited treatment options. The company is advancing lasofoxifene, a selective estrogen receptor modulator (SERM) in Phase 3 clinical trials (ELAINE-3) for metastatic breast cancer, and ATH-1105, a small molecule candidate for ALS that completed Phase 1 studies. The company in-licensed lasofoxifene from Sermonix Pharmaceuticals in December 2025 and is funded to advance through topline Phase 3 data in mid-2027.
Product overview
LeonaBio (formerly Athira Pharma) is a late-stage biopharmaceutical company developing novel small molecule drug candidates for devastating diseases with limited treatment options. The company operates two lead programs: lasofoxifene (Phase 3, for metastatic breast cancer) and ATH-1105 (Phase 1 completed, for ALS). The portfolio focuses on neurodegenerative diseases and oncology, with strategic licensing of Phase 3 assets to expand the pipeline.
Differentiator
Problem solved
Functional benefit
Products and services
- Lasofoxifene A novel, oral small molecule selective estrogen receptor modulator (SERM) currently in Phase 3 clinical trials (ELAINE-3) for metastatic breast cancer. The drug candidate aims to establish a potential new standard of care with peak annual U.S. sales projected at approximately $1 billion. In-licensed from Sermonix Pharmaceuticals; originally developed by Pfizer.
- ATH-1105 A novel, small molecule drug candidate for ALS (amyotrophic lateral sclerosis) that completed a Phase 1 clinical trial in healthy volunteers, showing positive safety and pharmacokinetic results. The company continues to advance this therapeutic candidate for neurodegenerative disease treatment.
Quantifiable outcome
- Phase 3 ELAINE-3 trial more than 50% enrolled with topline data expected mid-2027
- +2 more outcomes
Companies that use Athira Pharma
Customer profileSegments2 records
Ideal customer profiles1 record
Athira Pharma technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
Athira Pharma partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Sermonix PharmaceuticalscoreExclusive global license (excluding Asia and certain Middle Eastern countries) to develop and commercialize lasofoxifene, a Phase 3 selective estrogen receptor modulator for metastatic breast cancer. Deal terms include approximately $34.9 million in equity issuance, $16.8 million in third-party payments, monthly payments of $75,000 creditable against potential milestones totaling $100 million. Pfizer originally developed the asset and returned rights to Ligand Pharmaceuticals after a 2009 FDA complete response letter, with Sermonix later in-licensing the asset.
Scale indicators7 records
Recent moves5 records
Expansion highlights5 records
Athira Pharma competitors and assessment
Company assessmentMarket position
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Athira Pharma social profiles
Digital presenceAthira Pharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
Athira Pharma leadership team
Management profileNumber of profiles
Profiles8 records
Athira Pharma funding detail
Funding detailFunding overview
Funding rounds9 records
Investors32 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Athira Pharma M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Athira Pharma
What does Athira Pharma do?
Athira Pharma (operating as LeonaBio) is a clinical-stage biopharmaceutical company developing novel small molecule drug candidates for devastating diseases with limited treatment options. The company is advancing lasofoxifene, a selective estrogen receptor modulator (SERM) in Phase 3 clinical trials (ELAINE-3) for metastatic breast cancer, and ATH-1105, a small molecule candidate for ALS that completed Phase 1 studies. The company in-licensed lasofoxifene from Sermonix Pharmaceuticals in December 2025 and is funded to advance through topline Phase 3 data in mid-2027.
Is Athira Pharma a public or private company?
Athira Pharma is a public company. It is classified as public and is currently operating.
When was Athira Pharma founded?
Athira Pharma was founded in 2011. It employs 51 to 100 people.
Where is Athira Pharma based?
Athira Pharma is headquartered in Seattle, United States, in the North America region.
How does Athira Pharma make money?
One revenue line is on record: drug commercialization.
Does Athira Pharma have an API?
No public API is recorded for Athira Pharma.
What industry is Athira Pharma in?
Athira Pharma's product category is Clinical-Stage Biopharmaceutical Drugs. Its primary akta.pro industry code is HLAIACAA, Oncology Specialty Pharmaceuticals, with a secondary code of HLAIAAAB, Specialty Care Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.